Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

Abstract

The efficacy of lipid-encapsulated, chemically modified short interfering RNA (siRNA) targeted to hepatitis B virus (HBV) was examined in an in vivo mouse model of HBV replication. Stabilized siRNA targeted to the HBV RNA was incorporated into a specialized liposome to form a stable nucleic-acid-lipid particle (SNALP) and administered by intravenous injection into mice carrying replicating HBV. The improved efficacy of siRNA-SNALP compared to unformulated siRNA correlates with a longer half-life in plasma and liver. Three daily intravenous injections of 3 mg/kg/day reduced serum HBV DNA >1.0 log10. The reduction in HBV DNA was specific, dose-dependent and lasted for up to 7 d after dosing. Furthermore, reductions were seen in serum HBV DNA for up to 6 weeks with weekly dosing. The advances demonstrated here, including persistence of in vivo activity, use of lower doses and reduced dosing frequency are important steps in making siRNA a clinically viable therapeutic approach.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: HBV-specific siRNAs and in vitro potency.
Figure 2: Pharmacokinetic analysis of siRNAs.
Figure 3: Cytokine induction and toxicities associated with unmodified and chemically stabilized siRNA.
Figure 4: Activity of systemically administered siRNA-SNALP in an HBV mouse model.

References

  1. 1

    Chiu, Y.L. & Rana, T.M. siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034–1048 (2003).

    CAS  Article  Google Scholar 

  2. 2

    Layzer, J.M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766–771 (2004).

    CAS  Article  Google Scholar 

  3. 3

    Morrissey, D.V. et al. Activity of stabilized siRNAs in a mouse model of HBV replication. Hepatology 41, 1349–1356 (2005).

    CAS  Article  Google Scholar 

  4. 4

    Ambegia, E. et al. Stabilized plasmid–lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim. Biophys. Acta 1669, 155–163 (2005).

    CAS  Article  Google Scholar 

  5. 5

    Bally, M., Mayer, L., Hope, M. & Nayar, R. Pharmacodynamics of liposomal drug carriers: methodological considerations. in Liposome Technology, vol. III, 27–41, (CRC Press, London, 1993).

    Google Scholar 

  6. 6

    Fenske, D.B., MacLachlan, I. & Cullis, P. Long circulating vectors for the systemic delivery of genes. Curr. Opin. Mol. Ther. 3, 153–158 (2001).

    CAS  PubMed  Google Scholar 

  7. 7

    Fenske, D.B., MacLachlan, I. & Cullis, P.R. Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol. 346, 36–71 (2002).

    CAS  Article  Google Scholar 

  8. 8

    Judge, A. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457–462 (2005).

    CAS  Article  Google Scholar 

  9. 9

    Hornung, V. et al. Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263–270 (2005).

    CAS  Article  Google Scholar 

  10. 10

    Liu, F., Song, Y. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258–1266 (1999).

    CAS  Article  Google Scholar 

  11. 11

    Yang, P.L., Althage, A., Chung, J. & Chisari, F.V. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 99, 13825–13830 (2002).

    CAS  Article  Google Scholar 

  12. 12

    Samuel, C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778–809 (2001).

    CAS  Article  Google Scholar 

  13. 13

    Kim, D.H. et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22, 321–325 (2004).

    CAS  Article  Google Scholar 

  14. 14

    Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004).

    CAS  Article  Google Scholar 

  15. 15

    Wincott, F. et al. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res. 23, 2677–2684 (1995).

    CAS  Article  Google Scholar 

  16. 16

    Wheeler, J.J. et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 6, 271–281 (1999).

    CAS  Article  Google Scholar 

  17. 17

    Jeffs, L. et al. A scalable, extrusion free method for efficient liposomal encapsulation of plasmid DNA. Pharm. Res. 22, 362–372 (2005).

    CAS  Article  Google Scholar 

  18. 18

    Sandberg, J.A. et al. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. Pharmacol. 40, 1462–1469 (2000).

    CAS  PubMed  Google Scholar 

  19. 19

    Buckwold, V.E., Xu, Z., Chen, M., Yen, T.S. & Ou, J.H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 70, 5845–5851 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Roger Aitchison for statistical analysis, and Adrianna Wells for manuscript preparation.

Author information

Affiliations

Authors

Corresponding author

Correspondence to David V Morrissey.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Fig. 1

SNALP Lipids. (PDF 70 kb)

Supplementary Fig. 2

SNALP Structure. (PDF 685 kb)

Supplementary Fig. 3

In vivo localization of SNALP formulated Cy3-labeled siRNA in mouse livers. (PDF 481 kb)

Supplementary Fig. 4

Chemically stabilized HBV siRNA do not induce local interferon production in the liver. (PDF 81 kb)

Supplementary Fig. 5

Chemically stabilized HBV siRNA do not induce local interferon-beta production in the liver. (PDF 90 kb)

Supplementary Fig. 6

NOD.scid mice generate robust Interferon to unmodified siRNA. (PDF 47 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Morrissey, D., Lockridge, J., Shaw, L. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23, 1002–1007 (2005). https://doi.org/10.1038/nbt1122

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing